Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy

1. Coiffier, B.
2. Pro, B.
3. Prince, H.M.
4. Foss, F.
5. Sokol, L.
6. Greenwood, M.
7. Caballero, D.
8. Borchmann, P.
9. Morschhauser, F.
10. Wilhelm, M.
11. Pinter-Brown, L.
12. Padmanabhan, S.
13. Shustov, A.
14. Nichols, J.
15. Carroll, S.
16. Balser, J.
17. Balser, B.
18. Horwitz, S.